| |
Your Concise Update on Transplant Research
View as webpage | Forward to a colleague |
| |
|
|
| |
 |
|
 |
|
| |
| Vol. 11 | No. 4 |
| April 2011 |
|
| |
|
|
|
 |
| |
| Study tracks long-term survival of 10,000 allo-HCT recipients |
| This study of long-term survival analyzed 10,632 patients who were alive and disease free 2 years after myeloablative allogeneic hematopoietic cell transplantation (HCT). Outcomes were reported to the CIBMTR (Center for International Blood and Marrow Transplant Research) from 318 centers worldwide. Of these patients alive at 2 years post-transplant, 85% remained alive 10 years post-transplant. Advanced disease at transplant was the greatest risk factor for late relapse, which was the most common cause of death among patients with malignancies. The authors conclude that “the prospect for long-term survival is excellent for 2-year survivors of allogeneic HCT” but that prolonged follow-up is needed to prevent, identify, and treat late complications. |
| |
| Wingard JR, et al. J Clin Oncol, 2011; published online April 4. |
| |
| Review: HCT for adult T-cell leukemia/lymphoma |
| A review of hematopoietic cell transplantation (HCT) to treat adult T-cell leukemia/lymphoma, focusing on indications for HCT, conditioning regimens, stem cell sources, and transplant outcomes. Also discussed are clinical presentations of four T-cell leukemia/lymphoma variants (and their prevalence): acute (60%), lymphomatous (20%), chronic (15%) and smoldering (5%). |
| |
| Jabbour M, et al. Bone Marrow Transplant, 2011; published online Feb. 28. |
| |
| NCI recommendations for prevention and treatment of relapse after HCT |
| A summary report from the National Cancer Institute (NCI) on the biology, prevention, and treatment of relapse after allogeneic hematopoietic cell transplantation (HCT). The report summarizes the recommendations from each of six working committees, and outlines three research initiatives to address the issue of relapse after HCT. The research initiatives include developing clinical trial networks, creating a network of biorepositories, establishing definitions for disease-specific response and relapse, and recommendations for monitoring minimal residual disease. |
| |
| Bishop MR, et al. Biol Blood Marrow Transplant, 2011; 17(4): 443-454. |
| |
| Impact of pre-transplant MRD in AML outcomes |
| A single-center retrospective study examining the prognostic utility of pre-transplant minimal residual disease (MRD) in 99 consecutive patients with acute myeloid leukemia (AML) in first remission who underwent myeloablative allogeneic transplantation. As determined by multiparametric flow cytometry, 24 (24%) had MRD before transplant. Two-year overall survival was 30.2% vs. 76.6% in MRD-positive and MRD-negative patients, respectively. In a multivariate analysis adjusted for patient and disease factors, MRD-positive patients had significantly higher overall mortality (HR 4.05; 95% CI, 1.90-8.62; p<0.001) and relapse (HR 8.49; 95% CI, 3.67-19.65; p<0.001) than MRD-negative patients. |
| |
| Walter RB, et al. J Clin Oncol, 2011; 29(9): 1190-1197. |
| |
| Review: HCT to treat Type I diabetes mellitus |
| A review of animal and human studies that have examined the role of hematopoietic cell transplantation (HCT) in treating Type I diabetes mellitus (T1D). The review discusses autologous and allogeneic transplantation, combining allogeneic HCT with pancreas or islet cell transplantation, the possibility of generating surrogate β cells from bone marrow stem cells, and the potential utility of bone marrow mesenchymal stem cells in treating T1D. |
| |
| Mabed M. Biol Blood Marrow Transplant, 2011; 17(4): 455-464. |
| |
| |
| Visit the NMDP at the ONS Annual Congress |
| Medical professionals attending the Oncology Nursing Society (ONS) Annual Congress April 28-May 1 in Boston are invited to visit the NMDP’s exhibit booth #242. Order new patient education resources, view clinical guidelines, and learn about patient newsletters for post-transplant survivors.ONS information |
| |
| Clinical guidelines app: now available on Blackberry |
| You can now instantly access our Transplant Clinical Guidelines through a free mobile app. The app contains clinical decision-making information from the NMDP/ASBMT Timing for Transplant Consultation Guidelines and Post-Transplant Care Guidelines. The app is now available via Blackberry, iPhone®, iPad™, Android, and mobile web.Download free app |
| |
 |
| |
 |
| |
| Supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc., provided to the National Marrow Donor Program through the Be The Match Foundation®, the funding partner of the NMDP. |
| |
|
|
|
|
| |
| |
| Advances in Transplantation is an electronic newsletter published monthly by the National Marrow Donor Program (NMDP). This newsletter is sent only to those individuals who have requested to receive clinical education updates from NMDP. |
| |
| If this e-mail message was forwarded to you and you’d like Advances in Transplantation delivered directly to you, please subscribe. If you would like to stop receiving Advances in Transplantation, please unsubscribe. |
| |
| If you are a member of the NMDP Be The Match Registry®, unsubscribing to the Advances in Transplantation e-newsletter does not change your status on the registry. The NMDP may still contact you by e-mail, postal mail or telephone if a patient needs you or to request that you update your address. |
| |
| E-mail your comments or suggestions |
| |
| |
|
|
|
| |
|
|
|
